Physician profile
Meredith A Howard
NPI 1467104661
$3,471.63
in general payments reported to CMS, 2019-2025
20 companies · $1,784 in 2025
The $1,784 reported for 2025 was more than what 97% of Registered Nurse providers received nationally (typical 2025 total: $73.55).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,687 · 2025: $1,784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,340 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,340.47 |
| Education | $131.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $562.63 | 2024-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $441.21 | 2024-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $301.38 | 2024-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Lundbeck LLC | $286.72 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $263.98 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Supernus Pharmaceuticals, INC. | $211.99 | 2024-2025 | Qelbree |
| Alkermes, INC. | $172.81 | 2024-2025 | Aristada, Lybalvi |
| Tris Pharma INC | $168.89 | 2024-2025 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $161.21 | 2024-2025 | Fanapt, Hetlioz |
| Corium, LLC | $138.08 | 2024-2025 | Azstarys |
| Noven Therapeutics, LLC | $134.78 | 2024-2025 | Xelstrym, Secuado |
| Indivior INC. | $110.90 | 2024-2025 | Sublocade |
| Takeda Pharmaceuticals U.S.A., INC. | $108.79 | 2024-2025 | Trintellix |
| Abbvie INC. | $102.79 | 2024-2025 | |
| Harmony Biosciences LLC | $73.09 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $56.43 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $49.22 | 2025 | Auvelity |
| Bausch Health US, LLC | $49.15 | 2025 | Aplenzin, Wellbutrin |
| Collegium Pharmaceutical, INC. | $38.86 | 2025 | Jornay Pm |
| Tempus Ai, INC | $38.72 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.